Influence of CYP2C19 polymorphisms on efficacy of tamoxifen on the breast cancer patients: a Meta-analysis
10.13699/j.cnki.1001-6821.2018.10.026
- VernacularTitle:细胞色素P450 2C19基因多态性对服用他莫昔芬乳腺癌患者疗效影响的Meta分析
- Author:
Yi-Yun GUO
1
;
Hai-Tang XIE
;
Xiao-Hui HUANG
Author Information
1. 安徽医科大学药学院
- Keywords:
cytochrome P450 2C19;
tamoxifen;
beast cancer;
systematic review;
Meta-analysis
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(10):1230-1233
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the relationship between cytochrome P450 2C19 (CYP2C19) polymorphisms and effect of the tamoxifen (TAM) in the treatment of beast cancer by performing a meta-analysis.Methods The relevant DataBase were systematically searched for clinical studies on the CYP2C19 polymorphisms of TAM for breast cancer patients.The literatures were screened according to the inclusion and exclusion criteria.Then,the data were extracted and the methodologically quality of included studies were also examined,recurrence-free survival (RFS) as an evaluation indicator.Meta-analysis was carried out by using RevMan 5.3 software from Cochrane Network.Results A total of 8 studies involving 3261 subjects were included.The results of meta-analysis showed that there was no significant difference in CYP2C19 * 2 gene mutation for RFS of breast cancer patients using TAM (OR =1.13,95％ CI:0.92-1.40,P ＞ 0.05),as well as CYP2C19 * 17 (OR =1.22,95％ CI:0.94-1.57,P ＞ 0.05).Conclusion The CYP2C19 polymorphisms might be not associated with the effect of TAM on the breast cancer patients.
